This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.
DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)
Medical Information
DARZALEX FASPRO - Partial or Incomplete Administration
Last Updated: 07/17/2026
SUMMARY
- There are no systematically collected data to support the safety and efficacy of DARZALEX FASPRO when considering partial or incomplete dose administration. Clinical judgment should be exercised when considering any dosing intervals outside of those listed in the DARZALEX FASPRO Prescribing Information. Johnson & Johnson cannot recommend any practices, procedures, or dosing modifications that deviate from product labeling and are not approved by the regulatory agencies.
- The recommended dose of DARZALEX FASPRO is 1,800 mg/30,000 units (1,800 mg daratumumab and 30,000 units hyaluronidase) administered subcutaneously, over approximately 3-5 minutes.1
- If a dose of DARZALEX FASPRO is missed, administer the dose as soon as possible and adjust the dosing schedule to maintain the dosing interval.1
- No dose reductions of DARZALEX FASPRO are recommended. Consider withholding DARZALEX FASPRO to allow recovery of blood cell counts in the event of myelosuppression.1
Literature Search
A literature search of MEDLINE®
databases (and/or other resources, including internal/external databases) was conducted on 14 July 2026.
References
| 1 | DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.; https://www.jnjlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX+Faspro-pi.pdf |
Would you like to clear and leave your conversation? Message history will be lost.